A mouse model of systemic lupus erythematosus responds better to soluble TACI than to soluble BAFFR, correlating with depletion of plasma cells.

about

A mouse model of systemic lupus erythematosus responds better to soluble TACI than to soluble BAFFR, correlating with depletion of plasma cells.

Item

http://www.wikidata.org/entity/Q41066685

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

A mouse model of systemic lupu ...... ith depletion of plasma cells.

@en

type

Item

label

A mouse model of systemic lupu ...... ith depletion of plasma cells.

@en

prefLabel

A mouse model of systemic lupu ...... ith depletion of plasma cells.

@en

P1476

A mouse model of systemic lupu ...... ith depletion of plasma cells.

@en

P2093

Henry Hess

http://www.w3.org/2001/XMLSchema#string

Josquin Nys

http://www.w3.org/2001/XMLSchema#string

Michele Vigolo

http://www.w3.org/2001/XMLSchema#string

Philipp Haselmayer

http://www.w3.org/2001/XMLSchema#string

P2860

BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth

TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease

The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed

Impaired IgA class switching in APRIL-deficient mice

NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily

APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth

BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2

BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator

Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency

BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases

P304

1075-1085

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/EJI.201746934

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Pascal Schneider

P577

2017-04-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28383107

http://www.w3.org/2001/XMLSchema#string

P932

5518279

http://www.w3.org/2001/XMLSchema#string